Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Stephens

Showing results (1011-1020 of 1,072) with videos related to

Pageof 108
Sort By:
Annals of Clinical and Translational Neurology|January 4, 2024
Lower limb muscle MRI fat fraction is a responsive outcome measure in CMT X1, 1B and 2ACarolynne M Doherty, Jasper M Morrow, Riccardo Zuccarino, et al.
Science Translational Medicine|April 15, 2016
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependenceJustin M Balko, Luis J Schwarz, Na Luo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classesJ H Chung, E Sanford, A Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular TestingAlexa B Schrock, Garrett M Frampton, Dana Herndon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Neoplasia (New York, N.Y.)|June 24, 2014
A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomasJason M Foulks, Kent J Carpenter, Bai Luo, et al.
Nature Medicine|October 29, 2013
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerA Vaishnavi, M Capelletti, A T Le, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2014
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasmsRaajit Rampal, Jihae Ahn, Omar Abdel-Wahab, et al.
Cancer Discovery|April 23, 2016
EGFR Fusions as Novel Therapeutic Targets in Lung CancerKartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, et al.
Pageof 108

Showing results (1011-1020 of 1,072) with videos related to

Sort By:
Pageof 108
Annals of Clinical and Translational Neurology|January 4, 2024
Lower limb muscle MRI fat fraction is a responsive outcome measure in CMT X1, 1B and 2ACarolynne M Doherty, Jasper M Morrow, Riccardo Zuccarino, et al.
Science Translational Medicine|April 15, 2016
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependenceJustin M Balko, Luis J Schwarz, Na Luo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classesJ H Chung, E Sanford, A Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular TestingAlexa B Schrock, Garrett M Frampton, Dana Herndon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Neoplasia (New York, N.Y.)|June 24, 2014
A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomasJason M Foulks, Kent J Carpenter, Bai Luo, et al.
Nature Medicine|October 29, 2013
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancerA Vaishnavi, M Capelletti, A T Le, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2014
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasmsRaajit Rampal, Jihae Ahn, Omar Abdel-Wahab, et al.
Cancer Discovery|April 23, 2016
EGFR Fusions as Novel Therapeutic Targets in Lung CancerKartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, et al.
Pageof 108